Earnings Preview

REGENXBIO

04/08/2026 14:52

REGENXBIO Inc. RGNX.OQ RGNX.O is expected to  show a rise in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026
The Rockville Maryland-based  company is expected to report a 448.4% increase in revenue to $117.127 million from $21.36 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
​LSEG's mean analyst estimate for REGENXBIO Inc. is for earnings of 6 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for REGENXBIO Inc. is $22.50, about 125.9% above its last closing price of $9.96
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.33
-1.34
-1.72
Missed
-28.5
Dec. 31 2026
-0.86
-0.96
-1.30
Missed
-36
Sep. 30 2025
-1.32
-1.31
-1.20
Beat
8.1​
Jun. 30 2025
-1.06
-1.10
-1.38
Missed
-25.5
​​Mar. 31 2025
0.53
0.48
0.12
Missed
-75.1
Dec. 31 2024
-1.24
-1.15
-1.01
Beat
11.9​
Sep. 30 2024
-1.11
-1.12
-1.17
Missed
-4.3
Jun. 30 2024
-1.30
-1.29
-1.05
Beat
18.7
This summary was machine generated August 4 at 13:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)